GlassScriptPhysician profile
Ahmad Hajj
NPI 1043287345
$97,440.75
in general payments reported to CMS, 2019-2025
15 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $20K · 2021: $42K · 2022: $7,302 · 2023: $163 · 2024: $6,087 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,000 · Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,000.00 |
| Food and Beverage | $389.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $49,048.80 | 2021-2022 | |
| Advanced Orthopaedic Solutions, INC. | $41,313.77 | 2019-2020 | |
| Citieffe, INC. | $6,000.00 | 2024 | |
| Medacta USA, INC. | $413.43 | 2022 | |
| Stryker Corporation | $310.08 | 2020-2025 | Gamma, Variax, Pangea |
| Teva Pharmaceuticals USA, INC. | $110.35 | 2022-2023 | Austedo Xr |
| Globus Medical, INC. | $55.51 | 2021-2023 | Ankle Fracture System |
| Dynasplint Systems INC. | $43.90 | 2025 | Dynasplint |
| Ermi LLC | $28.48 | 2019 | |
| Cmp Pharma, INC. | $24.08 | 2021 | |
| Sumitomo Pharma America, INC. | $22.13 | 2024 | Gemtesa |
| Organogenesis INC. | $19.64 | 2025 | Apligraf |
| Pacira Pharmaceuticals Incorporated | $18.77 | 2020 | |
| Zimmer Biomet Holdings, INC. | $16.95 | 2019 | |
| Lilly USA, LLC | $14.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Hajj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.